FDA clearance is a critical step in drug development, indicating that PM359 has potential therapeutic value and can now proceed to clinical trials. This news is likely to be viewed positively by investors, as it not only validates Prime Medicine's research and development capabilities but also opens up the possibility of a new treatment option for Chronic Granulomatous Disease. The anticipation of initial clinical data in 2025 further adds to the potential long-term value of this development.